The spectrum of Alzheimer's disease
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Alzheimer's disease diagnosis using brain scans is complex. Enlarged choroid plexus (ChP) and other brain volume changes do not reliably predict AD, suggesting diverse disease subtypes.
Area Of Science
- Neurology
- Neuroimaging
- Alzheimer's Disease Research
Background
- Hippocampal (H) and inferior parietal lobule (IPL) atrophy are standard in Alzheimer's disease (AD) diagnostics.
- The diagnostic role of an enlarged choroid plexus (ChP) in AD remains uncertain.
- Investigating volumetric changes in AD is crucial for understanding disease heterogeneity.
Purpose Of The Study
- To investigate the predictive value of enlarged choroid plexus (ChP) in Alzheimer's disease (AD).
- To examine the contribution of MRI-based volumetric brain changes in predicting AD.
- To analyze the AD Neuroimaging Initiative (ADNI) cohort for volumetric alterations.
Main Methods
- Utilized MRI volumetry on the AD Neuroimaging Initiative (ADNI) cohort (N=872).
- Assessed individual and combined volumetric changes in the hippocampus (H), choroid plexus (ChP), and inferior parietal lobule (IPL).
- Correlated volumetric findings with AD diagnosis and longitudinal changes.
Main Results
- No single volumetric brain change or combination reliably predicted AD diagnosis.
- A significant portion of AD patients (45%) showed no volumetric brain changes, even longitudinally.
- Observed volumetric changes in H, ChP, or IPL occurred in only a subset of AD patients (19%, 12%, 5% respectively).
Conclusions
- Amyloid-beta peptides contribute to brain atrophy in only a subset of amyloid PET-CT positive AD patients.
- Brain volumetric phenotypes in AD are diverse, suggesting unique disease entities within the AD spectrum.
- Findings support the concept of AD heterogeneity, similar to other neurodegenerative proteinopathies.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...